Variable expression levels which controls how strongly the antibodies bind to tumor-associated antigens (TAA)
Platforms
Home
/
Innovation
LeadsBody
(CD3 T-Cell Engager platform)
To achieve an optimal balance between safety and efficacy of T-cell engagers, we have developed a proprietary LeadsBody platform capable of facilitating diverse modifications to molecular designs of CD3-targeted bispecific antibodies. These key modifications include:
Fine-tuning CD3 affinity with differentiated profiles of cytokine release
Conditional T-cell redirecting and activation mechanisms within tumor microenvironments
Differing spatial structures
Platform possesses these significant advantages:
Optimized proportions and affinities of TAA and CD3 binding domains directing the action of T-cell engagers to the tumor site, minimizing off-target toxicity
Structural optimizations inducing effective killing of target cells by T cells while reducing cytokine secretion
Both in vitro and in vivo studies, T-cell engagers exhibited durable antitumor effects with less T-cell exhaustion induction
X-body
(4-1BB Engager platform)
Our X-body platform leverages advanced antibody engineering technology to create differentiated bispecific antibodies in a 2:2 format with high yield, high purity and excellent druggability.
One achievement that came out of our X-body platform is Opamtistomig (LBL-024), a 4-1BB/PD-L1 bispecific antibody. Our unique molecular design enables Opamtistomig (LBL-024) to overcome the major hurdle of liver toxicity associated with 4-1BB, and to achieve synergistic antitumor effects through both immune activation and the alleviation of immune suppression.
Balance the affinity between tumor-associated antigens (TAA) and 4-1BB
Facilitate the crosslinking and activation of the 4-1BB receptor only when binding to TAA at tumor sites, thereby localizing 4-1BB activation in TAA expressing tumor microenvironment
Bolster the immune response within the tumor microenvironment, while mitigating the risk of systemic toxicities
TOPiKinectics
(ADC platform)
Our proprietary TOPiKinectics platform possesses these significant advantages:
Strong target binding and rapid internalization
Fc mutation and precise control of DAR to balance efficacy and toxicity
Bystander killing to address tumor heterogeneity
Stable conjugator without retro-Michael reaction
Improved ADC physicochemical property
A portfolio of Next-Gen ADC developed on TOPiKinectics platform
LBL-054-ADC：a monoclonal antibody-based ADC targeting CDH17
/
LBL-058：a T cell engager conjugate (TEC), combines a DLL3-targeted bispecific T-cell engager with a topoisomerase I inhibitor (TOP1i) payload
/
LBL-061：a next-generation bispecific ADC targeting both EGFR and PD-L1
Leads Biolabs © Nanjing Leadsbiolabs Co., Ltd. | Su ICP No. 18069235